Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-03-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: linechemotherapyplacebomricancer
  Phrases that lowered it: and safetyefficacy andjapanesesafety ofthe efficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Maximum age: 99 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 132 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past termination rate: 8.2% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 23.0% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 96.1% (raises risk) · Drug's FDA history
• Sponsor's past trials: 1198 (raises risk) · Sponsor's track record
• Keywords listed: 0 (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients NCT01063517 · started 2010 · scored riskier than 69% of active trials completed
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer NCT01579578 · started 2012 · scored riskier than 66% of active trials terminated
• Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer NCT01084330 · started 2010 · scored riskier than 69% of active trials completed
• Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma NCT04209686 · started 2020 · scored riskier than 92% of active trials completed
• AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer NCT00719550 · started 2009 · scored riskier than 57% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.